Gene Therapy Manufacturing Workshop

Sponsored by Brammer Bio and MaxCyte
GENE THERAPY MANUFACTURING WORKSHOP
Strategies for BioManufacturing Viral-based Gene Therapy Vectors - Early-Stage Development Through Clinical Production
Welcome Remarks / Introduction:
Robert Preti, Ph.D., Chairman, Alliance for Regenerative Medicine (ARM); President, PCT, A Caladrius Company; SVP, Manufacturing and Technical Operations, Caladrius Biosciences
Chair:
Jessica Carmen, Ph.D., Director of Business Development, Cellular Therapy Partnerships, MaxCyte
Speakers:
James Brown, Ph.D., VP, Corporate Development, Aldevron
Matthew Caple, VP, Site Operations, Brammer Bio
Mike Kelly, Director, Asset Leadership and Portfolio Management, Gene Therapy, Biogen
Michael Roberts, Ph.D., Chief Scientific Officer, Synpromics

[@nickie1438]

wow very interesting- so the suggestion (at around 40 minutes of video) is to insert the therapeutic gene of interest in many serotypes and to see which one of these combinations is best for each individual patient dependent on their individual immune response?

[@nickie1438]

What is wrong with producing aav in adherent cell? Challenges and Pros?

[@fourshore502]

interesting but this was 4 years ago, soon 5, what has happened since?